{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:14:27Z","timestamp":1789496067540,"version":"build-2803163510"},"reference-count":55,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Our objective was to evaluate the association of serum biomarkers with baseline psoriatic arthritis (PsA) disease activity, pharmacodynamic effects of deucravacitinib on biomarker levels, and the relationship between biomarkers and clinical responses to deucravacitinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The phase 2 trial (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      identifier: NCT03881059) randomly assigned 203 patients with PsA 1:1:1 to placebo, deucravacitinib at 6 mg once daily (QD), or deucravacitinib at 12 mg QD. Serum biomarkers associated with the interleukin 23 (IL\u201023) pathway (IL\u201017A, \u03b2\u2010defensin [BD\u20102], and IL\u201019), type I interferon pathway, inflammation, and collagen matrix turnover were measured by immunoassay. Clinical responses (\u226575% improvement from baseline in the Psoriasis Area and Severity Index [PASI75] and \u226520% improvement from baseline in American College of Rheumatology criteria [ACR20] responses) were measured at week 16. Hematologic variables were also assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      IL\u201017A, BD\u20102, and IL\u201019 had a modest association with PASI scores (r = 0.4, r = 0.56, and r = 0.5, respectively) at baseline. In deucravacitinib groups, IL\u201017A, BD\u20102, IL\u201019, C\u2010X\u2010C motif ligand 9 (CXCL9), CXCL10, C\u2010reactive protein, matrix metalloproteinase 3, and collagen type 4 degradation marker levels were significantly reduced at week 16 versus baseline (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.01); higher levels of IL\u201023 pathway\u2013associated biomarkers predicted higher PASI75 and ACR20 response rates in deucravacitinib\u2010treated patients. Significantly higher PASI75 response rates were seen in patients with high baseline IL\u201017A (odds ratio 15.76) and BD\u20102 levels (odds ratio 15.41) versus low baseline IL\u201017A and BD\u20102 levels. Changes in hematologic variables that are characteristic of JAK inhibition were not observed with deucravacitinib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Deucravacitinib significantly impacted biomarkers associated with Tyk2 signaling pathways of key inflammatory cytokines, including IL\u201023 and type I interferon, and those related to collagen matrix turnover. These biomarkers may predict treatment responses to deucravacitinib.<\/jats:p>\n                    <jats:p>\n                      <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                        <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/art42921-toc-0001-m.png\">\n                          <jats:alt-text>image<\/jats:alt-text>\n                        <\/jats:graphic>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.42921","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T04:09:32Z","timestamp":1716264572000},"page":"1397-1407","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses"],"prefix":"10.1002","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6607-6070","authenticated-orcid":false,"given":"Oliver","family":"FitzGerald","sequence":"first","affiliation":[{"name":"University College Dublin  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[{"name":"University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[{"name":"Swedish Medical Center  Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-1219","authenticated-orcid":false,"given":"Christopher","family":"Ritchlin","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center  Rochester New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-8877","authenticated-orcid":false,"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[{"name":"Medical University of Vienna and Hietzing Hospital  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Gao","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Hu","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslawa","family":"Nowak","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashis","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Catlett","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_2_8_5_1","unstructured":"Sotyktu US.Package insert. Bristol Myers Squibb;2022."},{"key":"e_1_2_8_6_1","unstructured":"Sotyktu Canada.Product monograph. Bristol Myers Squibb Canada Co;2022."},{"key":"e_1_2_8_7_1","unstructured":"Sotyktu Japan.Package insert. Bristol Myers Squibb K.K.;2022."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01261-8"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab135"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.619502"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.11.001"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664"},{"key":"e_1_2_8_13_1","unstructured":"ZhangJ DingY HuiL et al.Deucravacitinib an oral selective tyrosine kinase 2 inhibitor in Asian patients with moderate to severe plaque psoriasis: findings from the phase 3 POETYK PSO 3 trial. Presented at: Annual Congress of the European Academy of Dermatology and Venereology; September 7\u201310 2022; Milan Italy."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae014"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17074"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42391"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181472"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.2.148"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122259"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181089"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-20"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050312116671725"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","unstructured":"MeasePJ GoffeBS MetzJ et al.Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet2000;356(9227):385\u2013390.","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","unstructured":"ChimalakondaA BurkeJ ChengL et al.Selective inhibition of tyrosine kinase 2 with deucravacitinib (BMS\u2010986165) compared with janus kinase 1\u22123 inhibitors. Poster presented at: Annual Fall Clinical Dermatology Conference; October 29\u2212November 1 2020; Virtual meeting and at Las Vegas Nevada.","DOI":"10.25251\/skin.4.supp.108"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41609-z"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.308"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700453"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39800"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00754"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2016.1174328"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/785705"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.2287"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200316069"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-019-0267-6"},{"issue":"5","key":"e_1_2_8_38_1","first-page":"829","article-title":"Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis","volume":"36","author":"Gudmann NS","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.050963"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05774-9"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(05)80003-4"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020686"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15278"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1159\/000475809"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.06.038"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003042"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001679"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40921"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-015-0025-y"},{"issue":"2","key":"e_1_2_8_51_1","first-page":"318","article-title":"The mechanism of action of tofacitinib \u2010 an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge JA","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14403"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20936059"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11168.x"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.42921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:36:38Z","timestamp":1759952198000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.42921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1002\/art.42921"],"URL":"https:\/\/doi.org\/10.1002\/art.42921","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2023-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}